Simple item page
 

The Anti-Diabetic Potential of Baicalin: Evidence from Rodent Studies

cris.lastimport.scopus2025-10-23T06:58:02Z
cris.virtual.author-orcid0000-0002-9067-6682
cris.virtual.author-orcid0000-0002-6828-0534
cris.virtualsource.author-orcidff566057-8099-4bac-bd4c-896c46beaa7c
cris.virtualsource.author-orciddaf06652-dcef-4aa8-b66a-bdb14028e85d
dc.abstract.enBaicalin is a biologically active flavonoid compound that benefits the organism in various pathological conditions. Rodent studies have shown that this compound effectively alleviates diabetes-related disturbances in models of type 1 and type 2 diabetes. Baicalin supplementation limited hyperglycemia and improved insulin sensitivity. The anti-diabetic effects of baicalin covered the main insulin-sensitive tissues, i.e., the skeletal muscle, the adipose tissue, and the liver. In the muscle tissue, baicalin limited lipid accumulation and improved glucose transport. Baicalin therapy was associated with diminished adipose tissue content and increased mitochondrial biogenesis. Hepatic lipid accumulation and glucose output were also decreased as a result of baicalin supplementation. The molecular mechanism of the anti-diabetic action of this compound is pleiotropic and is associated with changes in the expression/action of pivotal enzymes and signaling molecules. Baicalin positively affected, among others, the tissue insulin receptor, glucose transporter, AMP-activated protein kinase, protein kinase B, carnitine palmitoyltransferase, acetyl-CoA carboxylase, and fatty acid synthase. Moreover, this compound ameliorated diabetes-related oxidative and inflammatory stress and reduced epigenetic modifications. Importantly, baicalin supplementation at the effective doses did not induce any side effects. Results of rodent studies imply that baicalin may be tested as an anti-diabetic agent in humans.
dc.affiliationWydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
dc.affiliation.instituteKatedra Fizjologii, Biochemii i Biostruktury ZwierzÄ…t
dc.contributor.authorSzkudelski, Tomasz
dc.contributor.authorSzkudelska, Katarzyna
dc.date.access2024-11-27
dc.date.accessioned2024-11-27T12:31:23Z
dc.date.available2024-11-27T12:31:23Z
dc.date.copyright2023-12-28
dc.date.issued2024
dc.description.abstract<jats:p>Baicalin is a biologically active flavonoid compound that benefits the organism in various pathological conditions. Rodent studies have shown that this compound effectively alleviates diabetes-related disturbances in models of type 1 and type 2 diabetes. Baicalin supplementation limited hyperglycemia and improved insulin sensitivity. The anti-diabetic effects of baicalin covered the main insulin-sensitive tissues, i.e., the skeletal muscle, the adipose tissue, and the liver. In the muscle tissue, baicalin limited lipid accumulation and improved glucose transport. Baicalin therapy was associated with diminished adipose tissue content and increased mitochondrial biogenesis. Hepatic lipid accumulation and glucose output were also decreased as a result of baicalin supplementation. The molecular mechanism of the anti-diabetic action of this compound is pleiotropic and is associated with changes in the expression/action of pivotal enzymes and signaling molecules. Baicalin positively affected, among others, the tissue insulin receptor, glucose transporter, AMP-activated protein kinase, protein kinase B, carnitine palmitoyltransferase, acetyl-CoA carboxylase, and fatty acid synthase. Moreover, this compound ameliorated diabetes-related oxidative and inflammatory stress and reduced epigenetic modifications. Importantly, baicalin supplementation at the effective doses did not induce any side effects. Results of rodent studies imply that baicalin may be tested as an anti-diabetic agent in humans.</jats:p>
dc.description.accesstimeat_publication
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if4,9
dc.description.number1
dc.description.points140
dc.description.reviewreview
dc.description.versionfinal_published
dc.description.volume25
dc.identifier.doi10.3390/ijms25010431
dc.identifier.issn1422-0067
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/2112
dc.identifier.weblinkhttps://www.mdpi.com/1422-0067/25/1/431
dc.languageen
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.pagesart. 431
dc.rightsCC-BY
dc.sciencecloudsend
dc.share.typeOPEN_JOURNAL
dc.subject.enhyperglycemia
dc.subject.enmetabolic dysregulation
dc.subject.enskeletal muscle
dc.subject.enadipose tissue
dc.subject.enliver
dc.subtypeReviewArticle
dc.titleThe Anti-Diabetic Potential of Baicalin: Evidence from Rodent Studies
dc.title.volumeSpecial Issue: The Role of Bioactive Compounds in Human Health and Disease
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.volume25